Paxman achieving a ‘cool’ impact across the United States
As of October 2017, the Paxman Scalp Cooling System has now been installed in 44 treatment sites across the United States in the first months since receiving clearance by The U.S. Food and Drug Administration (FDA). It is the only scalp cooler in the world to offer a single patient use cooling cap to each user.
81 Paxman scalp cooling systems can now be found in 44 key oncology sites across 14 states including Dana Farber Cancer Institute, the Memorial Sloan Kettering Cancer Center, Seattle Cancer Care Alliance, University California San Diego (UCSD), University of Wisconsin (UW) Health, Regional Cancer Care Associates (RCCA) and The US Oncology Network for use in their community based practices. Here is the full list.
The Paxman Scalp Cooling System has been developed by a British family who understand first-hand what it is like to lose hair due to cancer treatment. The concept behind the technology, which helps to reduce hair loss throughout chemotherapy, came when mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy induced hair loss.
The company has since been on a personal journey to ensure Sue’s legacy lives on by helping women around the globe minimise chemotherapy-induced hair loss and contribute to their quality of life.
Richard Paxman, CEO at Paxman said: “We have been delighted with how our scalp cooler has been embraced by US oncologists and patients and are honoured to have been able to introduce it at so many prestigious US centres. Chemotherapy induced hair loss is consistently ranked in the top five most distressing cancer chemotherapy side effects and we are working hard to ensure that breast cancer patients have a choice against hair loss.”
Chemotherapy works by targeting all rapidly dividing cells in the body. Hair is the second fastest dividing cell, and this is the reason why many chemotherapy drugs cause alopecia. The hair follicles in the growth phase are attacked, resulting in hair loss approximately two weeks after the commencement of the chemotherapy treatment.
The damage that chemotherapy causes to the hair follicle can be alleviated by using the scalp cooling treatment; also known as the 'cold cap'. It works by reducing the temperature of the scalp by a few degrees immediately before, during and after the administration of chemotherapy.
The Paxman Cooling Cap molds to all head shapes and sizes. The liquid coolant passes through the cap, extracting heat from the patient's scalp, ensuring an even, constant temperature is maintained to minimise hair loss.
The company have also introduced a US focused website to support American women through every step of their scalp cooling treatment. It features an online resource area designed to make the whole process easy as possible.
In addition, The Paxman Hub guides patients through the whole process from everything from billing, reimbursement, nurse and physician support programmes and logistics. Patients are provided with a personal Case Manager where they can then order and pay for their own scalp cooling cap and treatments. The Paxman Hub offers full support on patient information, payer coverage, coding, and patient assistance programmes.
The prevention of hair loss represents an important challenge in oncology, which affects over four million patients annually. By 2030 it is estimated it will affect over 6.7 million patients every year.
To find out more visit the Paxman team at the San Antonio Breast Cancer Conference 2018. Taking place from the 5-9 December the Paxman Scalp Cooling System will be located on Booth No.529, Hall 2 in the Henry B. Gonzalez Convention Center.
For more information visit www.paxmanscalpcooling.com
NOTES TO EDITORS
MEDIA CONTACT | For more information or to request more images please contact Julia Price:
DD: +44 (0) 7737 864878 e-mail: email@example.com